Zynex Inc
NASDAQ:ZYXI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.19
13.74
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Zynex Inc
Zynex Inc
Revenue
Zynex Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zynex Inc
NASDAQ:ZYXI
|
Revenue
$193.7m
|
CAGR 3-Years
19%
|
CAGR 5-Years
37%
|
CAGR 10-Years
32%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Revenue
$20.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
9%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Revenue
$15.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
Stryker Corp
NYSE:SYK
|
Revenue
$22B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Revenue
$41.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Revenue
$7.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
14%
|
|
Zynex Inc
Revenue Breakdown
Breakdown by Geography
Zynex Inc
Breakdown by Segments
Zynex Inc
|
Total Revenue:
184.3m
USD
|
|
Supplies:
125.5m
USD
|
|
Represent The Information Pertaining To Devices:
58.8m
USD
|
Zynex Inc
Glance View
Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. The company is headquartered in Englewood, Colorado and currently employs 774 full-time employees. The company went IPO on 2002-11-27. The Company’s devices are intended for pain management to reduce reliance on drugs and medications and provide rehabilitation and through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (IFC), neuromuscular electrical stimulation (NMES) and transcutaneous electrical nerve stimulation (TENS). The Company’s products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, and E-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream, Knee Braces and LSO Back Braces, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter, and HemeOx tHb Oximeter. CM-1500 is a Zynex fluid monitoring system.
See Also
What is Zynex Inc's Revenue?
Revenue
193.7m
USD
Based on the financial report for Sep 30, 2024, Zynex Inc's Revenue amounts to 193.7m USD.
What is Zynex Inc's Revenue growth rate?
Revenue CAGR 10Y
32%
Over the last year, the Revenue growth was 4%. The average annual Revenue growth rates for Zynex Inc have been 19% over the past three years , 37% over the past five years , and 32% over the past ten years .
You don't have any saved screeners yet
